{"id":"W3211577173","doi":"10.1016/j.jtho.2021.10.023","title":"CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"ca_institutions":"Humber River Regional Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Windsor Regional Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Alberta Cancer Foundation; Sunnybrook Health Science Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; Takeda Canada; Merck Sharp and Dohme; Cancer Australia; Astellas Pharma Canada; AbbVie; Roche; Novartis; Sanofi; Merck; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Platinum; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001666429,0.002156699,0.003109389,0.0005472896,0.0005012089,0.00128136,0.001260779,0.001929362,0.01242696],"category_scores_gemma":[0.001749481,0.0009280612,0.002052926,0.0005186521,0.00125136,0.001510376,0.0005609817,0.004772228,0.001853264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001671582,"about_ca_system_score_gemma":0.001975951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00256779,"about_ca_topic_score_gemma":0.007805804,"domain_scores_codex":[0.9993027,0.0003460983,0.00002702478,0.0001270045,0.00004282268,0.0001543702],"domain_scores_gemma":[0.9993368,0.0001423878,0.0001219319,0.00005679785,0.00003186144,0.0003101635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9660091,0.005502057,0.000634057,0.0004347233,0.0008600531,0.00004367526,0.00005387207,0.0006329709,0.003376136,0.0002019932,0.00231546,0.01993573],"study_design_scores_gemma":[0.9673696,0.03001316,0.001053749,0.00001467899,0.0002791935,0.00003054114,0.00001412936,0.0002777819,0.0001704218,0.000132497,0.0006326204,0.00001160439],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833746,0.003825502,0.0006090993,0.001859658,0.0009062713,0.003260838,0.002324468,0.0002673349,0.003572156],"genre_scores_gemma":[0.9817938,0.002114566,0.00167373,0.001906107,0.0004981211,0.00352081,0.002963634,0.00007841767,0.005450865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01242696,"threshold_uncertainty_score":0.04157227,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02016332716884563,"score_gpt":0.4295004179541777,"score_spread":0.4093370907853321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}